| Hold Ajanta Pharma target of Rs 318 Nirmal Bang - Moneycontrol.com |
|
|
Moneycontrol.com To expand its business scope the company is targeting new therapeutic segments namely - Gastroenterology, Orthopedic, Respiratory and Nephrology.” “We believe Ajanta Pharma is an ideal candidate for re-rating considering its brand concentrated business |